LisaChristopherStine

The Global Conference on Myositis in Lisbon was a great week of science, collaboration, and friendship. Our Portuguese colleagues did a magnificent job of welcoming nearly 700 attendees this year. It is clear that we’re finally entering a new era of therapeutics. #GCOM2026

Kudos to my colleague and co-first author @JuliePaikMD on this landmark work. Proud to have contributed to the trial design, including a steroid-sparing protocol and integration of patient-reported outcome measures — more on that to come. DOI: 10.1056/NEJMoa2503531 #Myositis

Delighted to see the VALOR trial, published today in @NEJM: brepocitinib (oral TYK2/JAK1 inhibitor) significantly improved the TIS vs. placebo in treatment-resistant #dermatomyositis (Δ15.3 pts; P<0.001), w/ superiority across all 9 key secondary endpoints — 🧵

@JuliePaikMD Congratulations, Julie. Grateful to be a small part of this story with everyone. It’s a great day and the beginning of a therapeutic era previously unseen in myositis.

Excited to share our phase 3 trial published today in The New England Journal of Medicine evaluating brepocitinib in dermatomyositis. In this randomized, placebo-controlled study—the largest myositis trial to date—brepocitinib 30 mg daily led to significant improvements across a validated composite myositis outcome measure, including skin disease activity, glucocorticoid tapering, and physical function. Three key takeaways: ⚡ Rapid onset of efficacy, with improvements observed as early as week 4 ⏳ Durable response through 52 weeks 🎯 Targeted mechanism modulating the IFN pathway—a central driver of disease—with meaningful steroid-sparing effects These findings support a shift toward more targeted, mechanism-based therapies in dermatomyositis. Grateful to have contributed as a co-first and co-corresponding author to the design and execution of this study, and to the patients and investigators across participating sites who made this work possible. nejm.org/doi/full/10.10…

ACR 2025 Division of Rheumatology Reunion. I love these people. 🩷

@minc798 Poke me Chicago

Luxury Parisian retailer Polene opening its 2nd US store on Chicago's Oak Street - at 116 E Oak St Other locations are Paris, NYC, London, Seoul, and Tokyo. The space was previously St. John which went to a smaller Oak St space in 2023. chicagobusiness.com/commercial-rea…

Calcinosis is a painful, disfiguring and debilitating complication of SSc and DM. Our study suggests that 18F-NaF PET/CT may have advantages over expert clinical exam or CT alone for detection/quantification of calcinosis. #myositis #ssc #calcinosis frontiersin.org/journals/nucle…

I am honored to participate in this Medscape IBM event with my friend and colleague @ElieNaddaf3

@JuliePaikMD What an amazing day!

Quick work trip to Boston with the lovely @DrLisaCS ! Breakfast and myositis fun before a long workday ahead! #myositis

Learning from a legend this morning.

@ericdeinmd @RichardPAConway @RheumNow I really appreciate your excellent summary posts, Eric.

@RichardPAConway on PMR #RNL2025 @RheumNow PMR mimics: look for mimics in unusual/refractory cases - Suspect the mimics to avoid undertreatment or over-treatment Conway: PMR is NOT easy. Easy to misdiagnosis, easy to mistreat. "One of our most challenging cases"

@liebowitz_jason congratulations, Jason!

To many doctors, genetic disease has always implied an inherited condition. Yet physicians are realizing that mutations present only in certain cells may help explain illnesses that were never considered “genetic” at all, @liebowitz_jason writes. theatlantic.com/health/archive…

@ElieNaddaf3 Fewer and fewer whole food healthy choices are available. Current estimates suggest that 73% of the United States food supply is ultra-processed. And highly palatable food (sugar/salt) is very easy to over-eat. This is a public health disaster.

Removing minerals from water will not fix it. But cutting down on McDonald’s and calorie-dense highly processed food, and addressing disparities in access to healthy food will definitely help!

@MymaAlbaydaMD @jhrheumatology @MedMarwin @VishPatelMD @doctorgsayre @CaoilfhionnMD @kekuchinad @KristenMathias @andreafava @BritAdlerMD @RachelWallwork @EleniTiniakou Thank you, Myma. What a wonderful evening for all of us. Glad it all came together so well.

Always such a fun time catching up with @jhrheumatology peeps at the Hopkins reunion at #ACR24! @DrLisaCS never fails to plan an amazing event! #pingpong #hopkins family

@MithuRheum @RheumOnePagers @JHRheumFellows @jhrheumatology This is incredible BTW, @MithuRheum. You never cease to amaze me.

🆕 The Great Debate at #ACR24: Is Mixed Connective Tissue Disease (MCTD) a distinct disease entity? 🗳️ Final Vote (n=430 votes) • 51% = MCTD *is* a unique disease • 49% = MCTD is not a unique disease @DrLisaCS #MCTD #Rheumatology

@MithuRheum @RheumOnePagers @JHRheumFellows @jhrheumatology We narrowly scraped by! #MCTD all the way!

@HardinDave @TheMyositisAssc @johns @HopkinsMedicine You were missed!

@DrLisaCS @TheMyositisAssc @johns @HopkinsMedicine Wish I could've been there!

We had a wonderful time hosting @TheMyositisAssc excursion this past Friday to visit the @Johns Hopkins Myositis Center. So glad we could showcase our amazing group. #jhrheum #myositis @HopkinsMedicine

@jerryw1976 @TheMyositisAssc @johns @HopkinsMedicine Oh! I am sorry too. Let's catch up soon.

@DrLisaCS @TheMyositisAssc @johns @HopkinsMedicine So sorry I didn’t get a chance to see you at the conference @drlisacs. Had a really nice time.

A big shout out to my amazing mentee and her collaborator. Dr. Julie Paik is brilliant and kind. Richly deserved, and patients will be the beneficiaries. Congratulations @JuliePaikMD !